Urotronic: HTX Urology set to participate in study for Urotronic's prostate treatment device

Urotronic announced that HTX Urology is participating in an FDA-cleared study for a minimally invasive device for treating enlarged prostates. Plymouth, Minn.-based Urotronic's Optilume BPH (benign prostatic hyperplasia, otherwise known as enlarged prostate) catheter system is an outpatient procedure designed to combine balloon dilation to open the prostate and local drug delivery to maintain symptom [...]The post HTX Urology set to participate in study for Urotronic's prostate treatment device appeared first on Drug Delivery Business.